Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2026-02-03 00:00:00 ET · period of report 2026-02-03 · accession 0001817160-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-03 | 2026-02-03 | NRIX | Hansen Gwenn | CSO | M - OptEx | $0.84 | +31.3K | 115.0K | +37% | +$26.3K |
| D | 2026-02-03 | 2026-02-03 | NRIX | Hansen Gwenn | CSO | M - OptEx | $0.00 | -31.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-03 | M | A | 31,333 | $0.84 | 115,005 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-02-03 | M | D | 31,333 | $0.00 | 0 | D | $0.84 · — to 2026-02-10 | 31,333 Common Stock | (F1) The option is fully vested. |